Subdural Hematoma Clinical Trial
Official title:
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of SDH with or without concomitant surgical evacuation.
The purpose of our study is to conduct a prospective cohort study to assess the safety and effectiveness of MMA embolization for the treatment of CSDH. All patients with CSDH presenting to the emergency room or to neurosurgical outpatient clinic will be screened for potential enrollment. If the subject is willing to participate an informed consent will be obtained. All patients presenting to the emergency room or in neurosurgery clinic with CSDH diagnosed on CT scan will be considered for the study. If the patient needs emergent evacuation for clinical reasons, patient will be taken for surgical evacuation before consideration of EMMA. Patients that are more likely to have recurrence after surgical evacuation are those with recurrent CSDH, on antiplatelet or antithrombotic treatment. The EMMA could be used as primary treatment or in conjunction with surgery in these patients or in patients who may not be good surgical candidate. Follow up - All patients will be followed after discharge from the hospital at 1, 3 and 6 months interval. The follow up at 1 and 3 months will include plain CT head of the patient, which is standard of care for most patients. The follow up at 6 months will be only clinical follow up. Patients will be assessed for recurrence of CSDH on CT scan of head. The size of the CSDH will be measured and compared to previous scans and peri-procedural morbidity and mortality related to EMMA will be sought. This will be done at 1 and 3 months post EMMA. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04402632 -
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
|
N/A | |
| Completed |
NCT03496545 -
Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05472766 -
Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma
|
N/A | |
| Not yet recruiting |
NCT06052124 -
Augmented Reality for Subdural Drain Placement
|
N/A | |
| Completed |
NCT02368366 -
Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI
|
N/A | |
| Terminated |
NCT01463878 -
Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study
|
Phase 4 | |
| Not yet recruiting |
NCT06119932 -
Evaluation of One Burr Hole Evacuation for Subdural Hematoma
|
||
| Completed |
NCT02618382 -
A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population
|
Phase 4 | |
| Completed |
NCT03153150 -
Start or STop Anticoagulants Randomised Trial (SoSTART)
|
Phase 3 | |
| Completed |
NCT04270955 -
Dartmouth Middle Meningeal Embolization Trial (DaMMET)
|
N/A | |
| Recruiting |
NCT06067750 -
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
|
||
| Not yet recruiting |
NCT05713630 -
The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma
|
Phase 3 | |
| Withdrawn |
NCT01605357 -
Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04500795 -
Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma
|
N/A | |
| Recruiting |
NCT04170582 -
Patient Registry for Patients With Chronic Subdural Hematoma
|
||
| Recruiting |
NCT05649904 -
AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis
|
N/A | |
| Recruiting |
NCT04211233 -
Diagnostic Subdural EEG-electrode And Subdural hEmatoma (DISEASE)
|
N/A |